Biblio

Author [ Title(Asc)] Type Year
Filters: Author is Reshef, Ran  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Mishkin AD, Shapiro PA, Reshef R, Lopez-Pintado S, Mapara MY. Standardized semi-structured psychosocial evaluation before hematopoietic stem cell transplantation predicts patient adherence to post-transplant regimen. Biol Blood Marrow Transplant. 2019.
P
Bolaños-Meade J, Hamadani M, Wu J, Malki MMAl, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, et al. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
N
Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, Sun H, Wang J, Yagita H, Mineishi S, et al. The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol. 2015.
M
Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, et al. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
I
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, et al. International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant. 2015.
Xu B, Gordillo CA, Delille EM, Malandrakis S, Assal A, Mapara MY, Reshef R. Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients. Eur J Haematol. 2023.
F
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Mishkin AD, Mapara MY, Barhaghi M, Reshef R. Fertility Concerns and Access to Care for Stem Cell Transplant Candidates with Sickle Cell Disease. Biol Blood Marrow Transplant. 2020.
E
Zewde MGetachew, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, et al. Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease. Transplant Cell Ther. 2021.
Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant. 2014.
D
Deol A, Sengsayadeth S, Ahn KWoo, Wang H-L, Aljurf M, Antin JHarry, Battiwalla M, Bornhäuser M, Cahn J-Y, Camitta B, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.